Visible Genetics gets access to PE Biosystems technology
This article was originally published in Clinica
PE Biosystems and Visible Genetics have ended their patent litigation over DNA sequencing equipment and formed a worldwide licensing and collaboration agreement, giving Visible access to certain patents and intellectual property owned or exclusively licensed by PE Biosystems. Visible Genetics will pay PE Biosystems a $25 million licensing fee over the next four years, as well as royalties based on sales.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.